Background: Alström syndrome (AS), a monogenic form of obesity, is caused by recessive mutations in the centrosome-and basal body-associated gene ALMS1. AS is characterized by retinal dystrophy, sensory hearing loss, cardiomyopathy, childhood obesity, and metabolic derangements.
Conclusion:
Severe insulin resistance and T2DM are the hallmarks of AS. However, patients with AS may present with multiple other endocrinopathies affecting growth and development. (J Clin Endocrinol Metab 103: [2707] [2708] [2709] [2710] [2711] [2712] [2713] [2714] [2715] [2716] [2717] [2718] [2719] 2018) A lström syndrome (AS) (Online Mendelian Inheritance in Man # 203800) is a monogenic form of obesity characterized by progressive retinal dystrophy, sensory hearing loss, cardiomyopathy, obesity, childhood-onset type 2 diabetes mellitus (T2DM), hypertriglyceridemia, and progressive hepatic and renal dysfunction in late childhood and adulthood (1) . The estimated prevalence of AS is 1 to 10 in 1,000,000 persons (2) . It is caused by recessive mutations in ALMS1 (Chr 2q13) (3, 4) . Although its function is not completely understood, evidence to date suggests that ALMS1 plays roles in ciliary function, cell cycle regulation, endosomal trafficking, cell migration, and extracellular matrix production (5) (6) (7) .
Approximately 700 cases of AS have been reported worldwide (8) since the disorder was first described in 1959 (9) . Chart reviews and family-completed questionnairebased descriptions of AS have been reported (10) (11) (12) ), yet few encompass systematic single-center phenotyping and none use comparison with a body mass index (BMI)-matched control cohort. To characterize further the endocrine and metabolic complications of AS and to elucidate the pathogenesis of obesity and metabolic dysregulation, we conducted a detailed evaluation of 38 patients with AS and 76 controls to compare body composition, fat distribution [including findings from magnetic resonance spectroscopy (MRS]) of liver and muscle], and endocrine-metabolic parameters.
Methods

Subjects
From February 2013 to June 2014, 38 patients who fulfilled the clinical diagnostic criteria for AS and had ALMS1 mutations from 32 families (Table 1) were evaluated at the National Institutes of Health (NIH) Clinical Center, with a protocol approved by the National Human Genome Research Institute Institutional Review Board (www.clinicaltrials.gov, NCT00068224). Patients were recruited through Alström Syndrome International, a support group for families and health care providers of patients with AS. For metabolic analyses, patients with AS were matched 1:2 with 76 volunteer control subjects by age, sex, race, and BMI. Control subjects with no known genetic disorder were participants of various clinical studies (1997 to 2014; NCT00001195, NCT00001522, NCT00001723, NCT00005669, NCT00006073, NCT00030238, NCT00320177, NCT00758108, NCT01517048) in the Section on Growth and Obesity at the Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH. All metabolic studies for the control subjects were approved by the Eunice Kennedy Shriver National Institute of Child Health and Human Development Institutional Review Board. Written informed consent was obtained from adults and parents or guardians of children and assent from children before participation.
Genetic testing
All patients with AS had prior genetic testing via Sanger sequencing, microarray-based arrayed primer extension, or targeted gene sequencing and custom analysis test as previously described (13) .
Clinical and laboratory assessments
Physical examination and fasting venous blood sample
All AS and control subjects were evaluated at the NIH Clinical Research Center. Participants underwent physical examination (by J.C.H. or M.G.-A.) and venous blood draw after 12-hour fast. Glucose, insulin, C-peptide, free fatty acids (FFAs), glucagon, triglycerides, high-density lipoprotein (HDL) cholesterol, alanine aminotransferase (ALT), aspartate aminotransferase, IGF-1 (measured by chemiluminescence immunoassay), TSH, free T4, T3, prolactin, cortisol, ACTH (measured by chemiluminescence immunoassay), calcium, phosphorus, 25-hydroxyvitamin D (25OHD), 1,25-hydroxyvitamin D, LH, FSH, HbA1c (measured by HPLC), and creatinine concentrations were measured by the NIH Department of Laboratory Medicine. Testosterone and estradiol were measured by HPLC tandem mass spectrometry at Mayo Medical Laboratories (Rochester, MN).
Mixed meal test
A mixed meal test (MMT) was performed in 25 participants with AS and 26 control participants, who ingested a standard breakfast shake consisting of Boost ® High Protein (Nestlé HealthCare Nutrition, Inc., Highland Park, MI; 55% carbohydrate, 24% protein, and 21% fat), 7 mL/kg (maximum 400 mL) over 5 minutes (14) . Blood samples were drawn from an intravenous catheter at 210, 0, 15, 30, 60, 90, 120, 150, and 180 minutes after consumption of the shake for measurement of glucose, insulin, C-peptide, FFA, and glucagon concentrations.
Body composition
Height was measured in triplicate to the nearest 0.1 cm with a stadiometer. Weight was measured with an electronic digital scale to the nearest 0.1 kg. Waist circumference measurements at the iliac crest were obtained in triplicate by a registered dietitian. Total percentage body fat was measured by dual-energy X-ray absorptiometry with the Hologic QDR-4500A or Hologic Discovery A (Hologic, Waltham, MA). Visceral and subcutaneous fat volumes at L2-3 and L4-5 were measured by abdominal MRI, and fat contents of liver and right lateral midthigh quadriceps muscle were assessed by MRS with the Philips Achieva 3.0T TX (Amsterdam, Netherlands). The percentage abdominal visceral fat was calculated as the total volume of visceral fat divided by the total volume of subcutaneous and visceral fat combined for the L2-3 and L4-5 slices.
Energy intake and expenditure
A hyperphagia questionnaire (15) was administered to the parents and caregivers of subjects age #18 years regarding their observations of the subjects in their usual home environment. Resting energy expenditure (REE) was assessed by indirect calorimetry (TrueOne® 2400 Canopy System; Parvo Medics, Sandy, UT or Vmax TM Encore Metabolic Cart; Viasys, Conshohocken, PA). Predicted REE was calculated with the MifflinSt. Jeor equation (16) .
Calculations and definitions
BMI z scores were calculated according to the age-and sexspecific Centers for Disease Control and Prevention 2000 standards for age $2 years (17) (25) . Insulin sensitivity during the MMT was assessed through the wholebody insulin sensitivity index (WBISI) with the following equation: 10,000/√[fasting glucose (mg/dL) 3 fasting insulin (mIU/mL) 3 mean glucose (mg/dL) 3 mean insulin (mIU/mL)] (26). (for three or more categories) tests compared categorical variables between groups. Independent-samples t tests and Pearson correlations were performed for continuous variables of normal distribution and skewed data that were normalized after log or arcsine square root transformation. Nonparametric data were analyzed by Mann-Whitney U tests. Analyses of covariance (ANCOVAs) compared variables between groups, adjusting for age, sex, race, and body composition. A P value ,0.001 (0.05/50) was considered significant after Bonferroni correction for multiple comparisons. Nominal P values are shown.
Results
Genetic testing results for patients with AS
The cohort included 32 families, with 5 families having multiple siblings with AS. Mutations in both alleles of ALMS1 were identified in 31 families, and in 1 family, only one (heterozygous) mutation was identified (Table 1 ). All mutations are predicted to result in premature protein truncation.
Endocrine function in AS
The 38 patients with AS (age 2 to 38 years), who had a high rate of obesity (76.3%), were compared with a group of 76 control subjects (age 2 to 48 years), whose selection was purposely enriched for obesity to match the high prevalence of obesity in patients with AS. Controls had comparable age, sex, race, and BMI z scores (Table 2) . Despite their similar mean BMI z score, the AS group had 14 (36.8%) patients with T2DM compared with none in the control group (P , 0.0000001). Six of the 14 patients with AS with T2DM were obese, 7 were overweight, and 1 was normal weight. Representative photographs of an overweight but nonobese patient with AS who had severe acanthosis nigricans, extreme insulin resistance, and T2DM necessitating 7 units/kg/d of insulin are shown in Supplemental Fig. 1 .
Height z score was significantly lower in patients with AS compared with controls (P = 0.00004, Table 2 ). Patients with AS and controls had similar arm span/ height ratios (P = 0.85, Table 2 ) and sitting/standing height ratios (P = 0.38, Table 2 ). IGF-1 was nominally lower in patients with AS compared with controls (P = 0.001).
Hypothyroidism was observed in 11 patients with AS, 28.9% of the cohort. Four patients were diagnosed with central hypothyroidism: two patients had midnormal free T4 but suppressed TSH while taking levothyroxine for a previous diagnosis of central hypothyroidism; two other patients had low free T4 and normal TSH (diurnal pattern abnormal for one and not tested for the other). Two patients with AS had evidence of autoimmune primary hypothyroidism (low free T4, elevated TSH, and positive antithyroid antibodies), and five patients with a previous diagnosis of hypothyroidism appeared to have antibody-negative primary hypothyroidism, with normal free T4, normal TSH, and negative antibodies while they were taking appropriate replacement doses of levothyroxine. In contrast, none of the control subjects had a previous diagnosis of hypothyroidism, and of the 66 control subjects who had thyroid function test results available, only 2 had elevated TSH values and none had low free T4. Mean TSH and T3 were similar between groups, but free T4 was nominally lower for AS (P = 0.002, Table 2 ).
Morning cortisol (P = 0.49) and morning ACTH (P = 0.13) were similar between groups (Table 2) . One patient with AS had a previous diagnosis of central adrenal insufficiency (2.6%, Table 3 ); no additional patients were diagnosed with adrenal insufficiency at evaluation. None (0%) of 29 patients with AS who had 24-hour urinary free cortisol measured had values above the reference range for age, compared with 3 (12%, P = 0.09) of 25 in the control group with urinary cortisol measured who had values above reference range for age, but none were greater than two times the upper limits of normal.
Serum calcium (P = 0.04), phosphorus (P = 0.01), and 25OHD (P = 0.004) were nominally higher, whereas plasma PTH (P = 0.01) was nominally lower and 1,25-hydroxyvitamin D (P = 0.61) was similar in patients with AS compared with control subjects (Table 2) . A higher percentage of patients with AS were prescribed vitamin D supplementation (55.3% in AS vs 15.8% in controls, P , 0.0001). After adjustment for age, sex, race, and BMI z score, 25OHD remained nominally higher in patients with AS (P = 0.009). In ANCOVAs adjusted for 25OHD, the difference in PTH was attenuated (P = 0.05).
Prolactin was normal for all participants with AS and similar between groups (P = 0.58, Table 2 ). Hypogonadism was observed in 57.1% of adults with AS (35.7% primary gonadal insufficiency with elevated gonadotropins; 21.4% central gonadotropin insufficiency with nonelevated or suppressed LH and FSH) but only in 6.7% of control adults (P = 0.005). Sex steroid-associated abnormalities in male patients with AS included microphallus (50%), undescended testes (11.1%), hypospadias (5.6%), small testes in adulthood (100%), and low testosterone in adulthood (42.9%) ( Table 3 ). Female patients with AS frequently had alopecia (40%, Supplemental Fig. 2 ), elevated testosterone (25%), hirsutism (15%, Supplemental  Fig. 2) , and oligomenorrhea or amenorrhea in adulthood (85.7%) ( Table 3) . Testosterone was nominally higher in female patients with AS compared with controls (51 6 39 vs 26 6 17 ng/dL, P = 0.002), and nominally lower in adult male patients with AS compared with controls (265 6 107 vs 475 6 169 ng/dL, P = 0.01). 
Comparison of metabolic parameters in patients with AS vs BMI-matched controls
Total body composition and fat distribution Total percentage body fat measured by dual-energy X-ray absorptiometry was similar between patients with AS and controls in both unadjusted (P = 0.89, Table 2 ) and adjusted analyses [covariates: age, sex, and race; adjusted mean (95% CI): patients with AS vs controls: 33.9% (31.1% to 36.9%) vs 35.1% (33.0% to 37.1%); P = 0.54]. Unadjusted lean mass and bone mineral content were nominally lower in patients with AS (Table 2 ) but similar after adjustment for the shorter stature of patients with AS (lean body mass: P = 0.25, and bone mineral content: P = 0.18). Waist circumference z score (normed by age and sex) was similar in patients with AS compared with controls in both unadjusted analysis (P = 0.30, Table 2 ) and after adjustment for race (P = 0.47). Patients with AS and controls had similar percentages of abdominal visceral fat at L2-5 (P = 0.26, Table 2 ), which remained comparable after adjustment for age, sex, and race (P = 0.15).
Liver and muscle fat content BMI z score was nominally positively correlated with liver fat percentage (r = 0.43, P = 0.002) and muscle fat percentage (r = 0.53, P = 0.001) with all subjects combined, and this relationship remained nominally significant when subjects were analyzed by separate diagnosis categories (all Ps , 0.05, Figs. 1A and 1B) . Mean liver fat content was significantly higher in patients with AS compared with controls (P = 0.0002, Table 2 ) and remained significant after we adjusted for age, sex, race, and BMI z score (P = 0.0005 Fig. 1C) , indicating that even after we controlled for severity of obesity, patients with AS had a higher percentage of liver fat. ALT and aspartate aminotransferase were significantly higher in AS in both unadjusted analyses (Ps , 0.001, Table 2 ) and after adjustment for age, sex, race, and BMI z score (Ps , 0.001, Figs. 1D and 1E ). Muscle fat content was nominally higher in patients with AS compared with controls (P = 0.02, Table 2 ), but this difference was eliminated after adjustment for age, sex, race, and BMI z score [AS vs controls: 4.9% (95% CI, 4.0% to 5.9%) vs 4.3% (95% CI, 2.9% to 5.8%), P = 0.50].
Energy balance
The parent-or caregiver-reported hyperphagia questionnaire total score was nominally higher in patients with AS vs controls (P = 0.003, Table 2 ) and remained nominally higher after we controlled for age and BMI z score (P = 0.03). REE was nominally lower in patients with AS vs controls (P = 0.02, Table 2 ) but no longer different after adjustment for age, sex, race, and lean body mass [1469 (95% CI, 1377 to 1561) vs 1510 (95% CI, 1398 to 1623) kcal/day, P = 0.59]. Patients with AS had a higher respiratory quotient in both unadjusted analysis (P = 0.0006, Table 2 ) and after adjustment for age, sex, race, and BMI z score (P = 0.0006, Fig. 2A ), indicating relatively greater utilization of carbohydrate vs fat as the energy substrate. The Mifflin-St. Jeor equation predicted REE in both patients with AS and controls equally well (P = 0.87).
Glucose homeostasis
Compared with controls, patients with AS had similar fasting glucose (P = 0.84, Table 2 ) but higher fasting C-peptide and insulin, with consequently higher homeostatic model assessment of insulin resistance (Ps , 0.001, Table 2 ). Both unadjusted and adjusted WBISI derived from the MMT were significantly lower in patients with AS (Ps , 0.001, Table 2 and Fig. 2B ). MMT glucose and insulin measurements and their adjusted area under the curve (AUC) values were higher in patients with AS (Ps , 0.001, Table 2 and Figs. 2C-2F) . Fasting FFA was similar between groups, and MMT FFA AUC was nominally higher in patients with AS (Table 2 ), but after adjustment for age, sex, race, and BMI z score, both fasting FFA (P = 0.13) and MMT FFA AUC (P = 0.32) were similar for patients with AS and controls. Fasting glucagon and MMT glucagon AUC were nominally higher in patients with AS (Table 2) , but neither was significant after we adjusted for age, sex, race, and BMI z score (fasting: P = 0.29; AUC: P = 0.06). HbA1c was nominally higher in patients with AS (Table 2 ) and significantly different after adjustment for age, sex, race, and BMI z score (P = 0.0002). After we excluded the subjects with diabetes (14 in patients with AS, none for controls), the outcomes were unchanged (data not shown). Thus, even nondiabetic patients with AS displayed higher glucose and greater insulin resistance compared with BMI z score matched controls.
Blood pressure
Patients with AS and controls had similar systolic and diastolic BP z scores (Table 2 ). Fifteen patients in the AS group had been taking antihypertensive medications prescribed by their home medical providers at baseline, whereas there was one taking antihypertensive medication in the control group (P , 0.0001). After we excluded those patients from the AS cohort, unadjusted systolic (P = 0.06) and diastolic (P = 0.23) BP z scores were not significantly different between patients with AS and controls, but after adjustment for age, sex, race, and BMI z score, nominally higher systolic BP z scores and no difference in diastolic BP z scores were observed in patients with AS (P = 0.03, Figs. 3A and 3B) . 
Lipid profile
Patients with AS had significantly higher triglycerides, significantly lower HDL-cholesterol, and nominally lower low-density lipoprotein (LDL) cholesterol in adjusted analyses (Table 2 ) and after adjustment for age, sex, race, and BMI z score (P values: 0.000003 for triglycerides, 0.00001 for HDL, and 0.002 for LDL). After we excluded subjects taking lipid-altering medications (eight in patients with AS, none for controls), outcomes were unchanged (Figs. 3C-3E ).
MS
The percentage (95% CI) of patients with MS in AS was 52.6% (35.8% to 69.0%) vs 5.3% (1.5% to 12.9%) among controls [relative risk 9.9 (2.8 to 46.0), P , 0.0000001, Fig. 3F ]. With all ages combined, the AS and control groups had similar serum creatinine and eGFR (Table 2 ), but in adults, patients with AS had nominally higher serum Cr (P = 0.04) and nominally lower eGFR (P = 0.009) than controls. For all MS components that were significantly greater in patients with AS compared with controls, this difference remained significant after we adjusted for eGFR (Ps , 0.001).
Discussion
In this study, we observed a high frequency of endocrine abnormalities in patients with AS and found the presence of MS to be 10 times higher in patients with AS compared with BMI-matched controls. The most commonly observed abnormalities in our AS cohort were obesity, T2DM, hypothyroidism (central and primary), hypogonadism (central and primary), hyperandrogenism in female patients, and short stature [with proportional body dimensions accompanied by low IGF-1, potentially corroborating previous reports of GH secretion insufficiency in AS (27) ]. Although unstimulated cortisol values were similar between AS and control groups, central adrenal insufficiency had been diagnosed in one patient with AS, indicating that, though less common than other endocrinopathies, cortisol deficit is a potential risk in AS. Together these findings point to the diverse role of cilia in the function of the hypothalamic-pituitary axis and peripheral endocrine organs.
The pathogenesis of obesity in AS is unclear, but rodent models suggest dual dysfunctions in central nervous system regulation of appetite (28) and adipocyte differentiation (29) . Alms1 is expressed in the hypothalamus, a key brain region for energy balance (28) . Foz/foz mice with a truncating mutation of Alms1 have normal ciliary formation, but cilia are not maintained postnatally, resulting in a reduction in the number of hypothalamic neuronal cilia (28) . Recently, a key receptor in the energy homeostasis regulating leptinmelanocortin pathway, melanocortin-4 receptor, was found to be localized to the primary cilia of hypothalamic neurons (30) . Peripherally, ALMS1 is expressed in preadipocytes (31) , and disruption of Alms1 induces alterations of adipocyte morphology and gene expression profiles (29) .
Our group previously reported higher serum leptin concentrations in AS and another hyperphagia-and obesity-associated ciliopathy, Bardet-Biedl syndrome, compared with BMI-matched controls (32) (33) (34) , an observation consistent with murine data showing that cilia are needed for leptin receptor trafficking (35) . Our current study expands the clinical phenotyping of human AS and examines energy balance by using a validated hyperphagia questionnaire and indirect calorimetry in patients with AS and BMI-matched controls. We observed that REE adjusted for lean body mass was comparable in patients with AS and controls but that the hyperphagia score trended higher, suggesting that higher intake rather than the lower metabolic rate is probably the primary driver for obesity in AS. Reduced activity thermogenesis caused by lower mobility due to visual and auditory impairments may also be a contributing factor that we did not directly assess in the current study.
Previous studies that have examined metabolic complications in patients with AS lacked an equally obese control group for comparison. By eliminating the confounding contribution of obesity by matching each subject with AS with two controls (of similar age, sex, race, and BMI z score), we were able to ascertain the scope of metabolic disease caused by AS independent of BMI. We also performed ANCOVAs adjusting for age, sex, race, and BMI z score and observed that all differences meeting the threshold for significance after multiple-comparison correction remained significant (P , 0.001), verifying that patients with AS and controls were well matched. The most striking feature of AS that we observed was the severity of insulin resistance, which was more than five times that of equally obese control subjects. The mechanism by which loss of ALMS1 function leads to insulin resistance has not been fully elucidated. In Alms1 GT/GT mice, insulin-stimulated translocation of GLUT4 to the plasma membrane is reduced (29) . Reduced expression of alms1 in zebrafish resulted in significantly decreased b-cell mass (36, 37) . Together, these animal data point to a combination of insulin resistance and relative insulin insufficiency in AS.
Based on our observations in this human study, we hypothesize that fat deposition in the liver and potentially skeletal muscle could play a key role in the insulin resistance of AS. Fat content of liver and muscle as measured by MRS was positively correlated with BMI for all subjects, but the curve for this relationship was shifted upward in AS, such that at any given BMI, patients with AS had more fat in the liver and quadriceps muscle compared with controls. Glucose uptake and utilization within the liver and muscle are critical for glycemic control (38) . Fat deposition could create an inflammatory milieu (as evidenced by elevated transaminases in our subjects with AS) that underlies the pathophysiology for the severe insulin resistance and accompanying hyperglycemia, dyslipidemia, and other MS components observed in AS. Interestingly, elevated LDL-cholesterol (which is not typically included in the criteria for MS but is a common complication of obesity) was not seen in our AS cohort, and in fact LDL-cholesterol was nominally lower in patients with AS compared with BMI-matched controls. The clinical significance is unclear but may be protective for patients with AS. Other investigators have also observed hepatic steatosis and fibrosis in AS (12), but our study demonstrates that the severity of liver disease is significantly higher than in obese controls, suggesting a direct role of ALMS1 dysfunction, independent of obesity, in the pathogenesis of liver disease in AS. In a study of patients with AS in the United Kingdom, higher baseline aortic pulse wave velocity was positively associated with the duration of diabetes and predicted occurrence of cardiovascular events during 5 years of follow-up (39) . Along the same line, longitudinal studies are needed to elucidate the temporal relationship between liver pathology and insulin resistance.
Conclusion
Endocrine problems are common in AS, with severe insulin resistance and T2DM causing significant morbidity, even in those who are not obese. Although aerobic exercise and restriction of simple carbohydrate intake are important foundations for the management of AS in the context of multidisciplinary team-based care (40) , identification of therapies that target the hypothalamic defects causing hyperphagia and the peripheral metabolic derangements causing deposition of fat in the liver and muscle are needed.
